Navigating the Peptide Landscape: A Data-Driven Decision Framework
Aggregated self-reported data from 5,532 accounts across 10+ peptides suggests that selecting a peptide is rarely a single decision — most individuals reference multiple compounds, indicating frequent comparison, switching, or stacking. Tirzepatide (4,795 mentions), Retatrutide (3,849), and Semaglutide (2,936) dominate as primary focus areas, while BPC-157, TB-500, and Ipamorelin reflect distinct secondary interest clusters.
Which Peptides Generate the Most Interest — and Why
GLP-1/incretin agonists account for over 75% of all peptide mentions:
- Tirzepatide — 4,795 mentions — most-referenced overall, noted for dual-agonist metabolic effects
- Retatrutide — 3,849 mentions — triple-agonist drawing interest for perceived energy and metabolic activation
- Semaglutide — 2,936 mentions — widely referenced as an accessible entry point with strong appetite suppression
- Cagrilintide — 1,268 mentions — emerging amylin analog of interest primarily as a plateau-breaking adjunct
Outside incretins, two distinct categories appear:
- Healing/recovery: BPC-157 (526), TB-500 (442)
- GH secretagogues: Ipamorelin (286), CJC-1295 (242), Tesamorelin (208)
- Tissue remodeling: GHK-Cu (271)
Semaglutide vs. Tirzepatide vs. Retatrutide: Key Decision Factors
Roughly half of all comparative accounts between tirzepatide and retatrutide center on energy. Self-reported data suggests tirzepatide-associated fatigue drives individuals toward retatrutide for its perceived stimulating effects attributed to the glucagon receptor component. Three axes shape switching decisions:
- Side effect profiles: Semaglutide is predominantly associated with GI effects (nausea, vomiting). Tirzepatide self-reports skew toward systemic complaints — fatigue, skin sensitivity, and localized site reactions. Retatrutide reports focus on elevated resting heart rate, though the profile is described as distinct from tirzepatide's lethargy.
- Plateau-driven switching: A prevalent pattern involves starting semaglutide, plateauing after several months, then transitioning to tirzepatide or stacking low doses of both. Observational data indicates further escalation to retatrutide when tirzepatide plateaus occur — a perceived "escalation ladder" across incretin generations.
- Appetite suppression quality: Tirzepatide is consistently favored for silencing "food noise" and producing immediate satiety. Semaglutide's suppression is characterized as more "physical." Retatrutide's comparable appetite suppression reportedly emerges only at 6 mg or above, with lower doses allowing more natural hunger signals.
Observational data also points to custom stacking — combining low-dose semaglutide (appetite control) with retatrutide (metabolic activation) — as a strategy of growing interest for managing plateaus without maximizing a single compound's dose.
Self-Reported Dosing Patterns Across Top Peptides
Over 400 tirzepatide, 200+ retatrutide, and 65+ semaglutide regimen mentions reveal distinct titration patterns.
Tirzepatide
5 mg weekly is the most frequently reported dose (n=98):
- 2.5 mg weekly — n=64 (common starting point)
- 5 mg weekly — n=98 (most reported)
- 7.5 mg weekly — n=71
- 10 mg weekly — n=71
- 12.5 mg weekly — n=31
- 15 mg weekly — n=54
A smaller subset (n=10) reported 5 mg every 5 days, suggesting experimentation with injection frequency.
Retatrutide
2 mg weekly is most frequently reported (n=53) across a 1–8 mg weekly range:
- 1 mg weekly — n=38
- 2 mg weekly — n=53
- 4 mg weekly — n=34
- 6 mg weekly — n=25
- 8 mg weekly — n=17
Semaglutide
The established 0.25–2.4 mg weekly escalation: 0.25 mg (n=22), 0.5 mg (n=10), 1 mg (n=9), 1.7 mg (n=7), 2.4 mg (n=7).
Transition Patterns
Self-reported data reflects notable uncertainty around switching between compounds — whether to taper or switch abruptly. No consensus approach has emerged, with individuals describing both cold-turkey switches and gradual taper-down protocols.
Switching, Stacking, and Long-Term Maintenance Patterns
A prevalent self-reported pattern involves starting on semaglutide, plateauing, then switching to tirzepatide or stacking low doses of both.
- Semaglutide is frequently retained at low doses for "food noise" suppression, while tirzepatide is valued for broader metabolic effects
- Cagrilintide is an emerging adjunct, commonly added to break plateaus on high-dose tirzepatide — often dosed midweek (Day 4–5) to counteract appetite return
- Self-reported data suggests a growing pattern of viewing these peptides as indefinite protocols, with weight regain upon cessation cited as a primary concern driving multi-year planning
Healing and Recovery Peptides: BPC-157, TB-500, and GH Secretagogues
BPC-157 (526 mentions) and TB-500 (442 mentions) are frequently referenced together, with joint pain and recovery as the primary focus. Self-reported dosing data is notably sparse (3–4 reports per regimen).
- GH secretagogues form a separate cluster: ipamorelin (286), CJC-1295 (242), tesamorelin (208) — dosing reports are even thinner (1–5 per regimen)
- GHK-Cu (271 mentions) sits at the intersection of recovery and cosmetic interest; 2 mg daily is the most noted regimen (n=9)
- BPC-157 regimens varied widely — 250 mcg 2x/week, 0.5 mg daily, 1 mg 2x/day, and 400 mcg daily each appeared in just 4 reports
Current Research Landscape
Only 31 matched articles appear in the available dataset, with zero head-to-head trials comparing different GLP-1 receptor agonists — the very comparisons that dominate real-world interest. Published literature skews heavily toward semaglutide in diabetes-specific contexts, leaving a conspicuous gap between peptide-vs-peptide questions being explored and the formal evidence base.
This page synthesizes 5,532 self-reported accounts from 1,684 unique individuals — a meaningful but non-representative sample with an AI relevance rate of just 50%, indicating substantial noise in the source data.
- All dosing, timing, and outcome data is self-reported and unverified
- No clinical trials directly comparing these peptides for the specific decision points described were identified among 31 matched research articles
- Several peptides referenced (e.g., retatrutide, cagrilintide) remain investigational and lack regulatory approval
- Observational data cannot establish causation, and selection bias is inherent in self-reported samples
- No information on this page constitutes a dosing recommendation
This content is for educational purposes only and does not constitute medical advice. All decisions regarding peptide use should involve a qualified healthcare provider.